DE69533311D1 - Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen - Google Patents

Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen

Info

Publication number
DE69533311D1
DE69533311D1 DE69533311T DE69533311T DE69533311D1 DE 69533311 D1 DE69533311 D1 DE 69533311D1 DE 69533311 T DE69533311 T DE 69533311T DE 69533311 T DE69533311 T DE 69533311T DE 69533311 D1 DE69533311 D1 DE 69533311D1
Authority
DE
Germany
Prior art keywords
interferon
type
autoimmune diseases
treating autoimmune
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69533311T
Other languages
English (en)
Other versions
DE69533311T2 (de
Inventor
Staley Armstrong Brod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26920717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69533311(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of DE69533311D1 publication Critical patent/DE69533311D1/de
Application granted granted Critical
Publication of DE69533311T2 publication Critical patent/DE69533311T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69533311T 1994-04-12 1995-04-11 Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen Expired - Fee Related DE69533311T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22663194A 1994-04-12 1994-04-12
US226631 1994-04-12
US40827195A 1995-03-24 1995-03-24
US408271 1995-03-24
PCT/US1995/004420 WO1995027502A1 (en) 1994-04-12 1995-04-11 Method of treating auto-immune diseases using type one interferons

Publications (2)

Publication Number Publication Date
DE69533311D1 true DE69533311D1 (de) 2004-09-02
DE69533311T2 DE69533311T2 (de) 2005-07-21

Family

ID=26920717

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533311T Expired - Fee Related DE69533311T2 (de) 1994-04-12 1995-04-11 Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen

Country Status (13)

Country Link
EP (1) EP0752884B1 (de)
JP (1) JPH09511989A (de)
KR (1) KR100424212B1 (de)
AT (1) ATE271879T1 (de)
AU (1) AU695260B2 (de)
CA (1) CA2187550A1 (de)
DE (1) DE69533311T2 (de)
DK (1) DK0752884T3 (de)
ES (1) ES2224124T3 (de)
IL (1) IL113280A (de)
NZ (1) NZ284276A (de)
SA (1) SA95160081B1 (de)
WO (1) WO1995027502A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
AU724689B2 (en) 1996-05-09 2000-09-28 Pharma Pacific Pty Ltd Method of treatment
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CZ2002521A3 (cs) * 1999-08-27 2002-05-15 Maxygen Aps Nové molekuly podobné interferonu beta
UA86749C2 (en) * 2002-09-27 2009-05-25 Байоджен Айдек Ма Инк. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в
CA2511209A1 (en) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co., Ltd. Agent for treatment of pemphigoid
US20210228687A1 (en) * 2018-06-01 2021-07-29 Ilc Therapeutics Ltd Compositions and methods relating to the treatment of diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease

Also Published As

Publication number Publication date
KR100424212B1 (ko) 2004-07-21
DK0752884T3 (da) 2004-11-22
EP0752884B1 (de) 2004-07-28
WO1995027502A1 (en) 1995-10-19
JPH09511989A (ja) 1997-12-02
KR970702063A (ko) 1997-05-13
IL113280A0 (en) 1995-07-31
IL113280A (en) 2004-12-15
ATE271879T1 (de) 2004-08-15
EP0752884A4 (de) 1999-04-07
CA2187550A1 (en) 1995-10-19
EP0752884A1 (de) 1997-01-15
NZ284276A (en) 2000-07-28
AU2283995A (en) 1995-10-30
AU695260B2 (en) 1998-08-13
ES2224124T3 (es) 2005-03-01
SA95160081B1 (ar) 2005-09-19
DE69533311T2 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
ATE338563T1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
DK0880350T3 (da) Behandling af dissemineret sklerose
BR9709068A (pt) Processo de tratamento.
DE69033487T2 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE58902737D1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
ATE342067T1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
ATE493978T1 (de) Behandlung von autoimmunerkrankungen
DE69614375D1 (de) Dermatologische zubereitung zur behandlung von aktinischen keratosen
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE297722T1 (de) Verwendung von gaba analoga wie gabapentin zur herstellung eines medikaments für die behandlung von entzündungserkrankungen
DE69622472T2 (de) Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
AT383612B (de) Verfahren zur herstellung eines neuen antigenen proteins des maul- und klauenseuchevirus
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
ATE135912T1 (de) Thienotricyclen zur behandlung von erkrankungen der bronchien
DE69220229D1 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder
MX9700413A (es) Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso.
UA15164A (uk) Спосіб детоксикації при захворюваhhях оргаhів гепатопаhкреатобіліарhої зоhи запальhого геhезу

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings
8339 Ceased/non-payment of the annual fee